University of Arizona R. Ken Coit College of Pharmacy

Dr Ivo Abraham Column: Biosimilars and the Commoditization of Treatments

October 26, 2022

Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, explores whether biosimilars should be considered a commodity and if the commodification of medications is sustainable as the market continues to expand.